Page 12 - emap_newsletter_V2
P. 12
eMAP – electronic EHA Medical HemAtology Program
months (see Figure). Furthermore, median OS was not reached, with a 27-month OS rate of 70.4% in all patients, 93.5%
for patients with sustained MRD negativity =6 months, and 90.8% for those with sustained MRD negativity =12 months (see
Figure).
The safety profile was manageable with no new treatment-related deaths detected. A total of 20 secondary primary
malignancies occurred in 16 patients, and one new case of parkinsonism was detected.
The study authors concluded that heavily pretreated patients with RRMM who received cilta-cel showed durable and deepening
responses after 27.7 months, with median PFS and OS not yet reached and a manageable safety profile.
WATCH WATCH
DR. REECE’S IN-DEPTH PRESENTATION OF THIS DR. REECE’S THOUGHTS ON THE RELEVANCE OF
ABSTRACT (~6 MINUTES) THESE DATA TO CANADIAN PRACTICE (~2 MINUTES)
CLICK HERE FOR THE LINK TO THE FULL ABSTRACT
TABLE OF CONTENTS 12
